Literature DB >> 2913371

Ureteral replacement using ileum in compromised renal function.

W B Waters1, G Herbster, V R Jablokow, D J Reda.   

Abstract

Ureteral replacement by ileum is an accepted technique in a highly selective patient population. Two major contraindications in using an ileal ureter are compromised renal function (serum creatinine greater than 2) and a functionally abnormal bladder. We used ileum to bridge a ureteral defect in animals with half of a solitary kidney and low grade azotemia to see if the antirefluxing mechanism of the lower ureter prevented further deterioration in renal function. Twelve female mongrel dogs underwent a right nephrectomy, followed by a left partial nephrectomy six weeks later. Group I (six dogs) had a six cm. segment of ileum interposed between the upper and lower ureteral segments (nonrefluxing). Group II (five dogs) had a ten cm. segment of ileum placed from the upper third of the ureter to the bladder (refluxing). Cystograms, intravenous pyelograms, serum electrolytes, BUN and creatinine were obtained preoperatively, six weeks after the right nephrectomy, one month after left partial nephrectomy and six months after ileal replacement prior to sacrifice. The BUN and creatinine deteriorated in Group II compared to Group I, p = .02 and p = 0.4 respectively (Mann-Whitney test). The BUN and creatinine also deteriorated between one month after left partial nephrectomy and six months after ileal replacement within Group II, p = .07 and p = .14, respectively (Wilcoxon matched-pairs test) but not in Group I. These data suggest that the antirefluxing mechanism of the lower ureter might prevent further deterioration in renal function. We feel that ileum can be used with caution, as an interposition in compromised renal function.

Entities:  

Mesh:

Year:  1989        PMID: 2913371     DOI: 10.1016/s0022-5347(17)40788-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

1.  Summary of 10 years' experience with an ileal low-pressure bladder substitute combined with an afferent tubular isoperistaltic segment.

Authors:  U E Studer; H Danuser; W Hochreiter; J P Springer; W H Turner; E J Zingg
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

2.  Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.

Authors:  Tzu-Yin Lin; Yuanpei Li; Qiangqiang Liu; Jui-Lin Chen; Hongyong Zhang; Diana Lac; Hua Zhang; Katherine W Ferrara; Sebastian Wachsmann-Hogiu; Tianhong Li; Susan Airhart; Ralph deVere White; Kit S Lam; Chong-Xian Pan
Journal:  Biomaterials       Date:  2016-07-22       Impact factor: 12.479

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.